Million-euro financial injection for cancer vaccines development
New European and US investors: Nouscom Raises €67.5 million in Oversubscribed Series C Financing Round
15-Nov-2023 -
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned ...
cancer
cancer immunotherapies
cancer vaccines
+5